Effect of salbutamol and inhaled sodium cromoglycate on the airway and neutrophil chemotactic activity in "fog"-induced bronchospasm

Gianna Moscato, Ciro Rampulla, Antonio Dellabianca, Ercole Zanotti, Stefano Candura

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

To investigate whether salbutamol and sodium cromoglycate (SCG) inhibit airway response and the associated mediator release induced by ultrasonic nebulation of distilled water (UNDW, "fog"), we measured the serum neutrophil chemotactic activity (NCA) during bronchial challenge with "fog" with and without premedication with placebo, salbutamol, or SCG in 10 subjects with asthma, in four sets of studies. To assess changes in airway caliber, we measured FEV1. To assess changes in NCA, we measured the maximal distance reached by neutrophils in a filter when neutrophils were challenged with the subject's serum in a Boyden chamber. Treatment with placebo did not change baseline FEV1 or serum NCA; however, FEV1 decreased and serum NCA increased (p <0.05) after inhalation of "fog." Treatment with SCG did not affect either FEV1 and baseline serum NCA. After inhalation of "fog," no significant bronchoconstriction nor NCA increase was observed in eight of 10 patients with maximal mean percent decrease in FEV1 of -4.26, SEM 0.99, and maximal mean percent increase in NCA of +8.6, SEM 5.28. In the two patients who developed a bronchoconstriction after challenge with SCG pretreatment, an associated significant increase in NCA was observed but did not affect baseline NCA. After inhalation of "fog," no significant decrease in FEV1 (maximal mean percent decrease FEV1, -6.71, SEM 0.17) nor significant increase in serum NCA (maximal mean percent increase NCA, +3.6, SEM 7.1) was observed in nine of 10 patients. After salbutamol, only one patient developed a bronchoconstrictive response to "fog" associated with a significant increase in serum NCA. These results suggest that both SCG and salbutamol may prevent the bronchoconstriction induced by "fog" by inhibiting mediator release.

Original languageEnglish
Pages (from-to)382-388
Number of pages7
JournalJournal of Allergy and Clinical Immunology
Volume82
Issue number3 PART 1
DOIs
Publication statusPublished - 1988

Fingerprint

Cromolyn Sodium
Bronchial Spasm
Albuterol
Weather
Neutrophils
Bronchoconstriction
Serum
Inhalation
Placebos
Premedication
Ultrasonics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Effect of salbutamol and inhaled sodium cromoglycate on the airway and neutrophil chemotactic activity in "fog"-induced bronchospasm. / Moscato, Gianna; Rampulla, Ciro; Dellabianca, Antonio; Zanotti, Ercole; Candura, Stefano.

In: Journal of Allergy and Clinical Immunology, Vol. 82, No. 3 PART 1, 1988, p. 382-388.

Research output: Contribution to journalArticle

@article{9b52bbef29cb4f659138116ff7a2700b,
title = "Effect of salbutamol and inhaled sodium cromoglycate on the airway and neutrophil chemotactic activity in {"}fog{"}-induced bronchospasm",
abstract = "To investigate whether salbutamol and sodium cromoglycate (SCG) inhibit airway response and the associated mediator release induced by ultrasonic nebulation of distilled water (UNDW, {"}fog{"}), we measured the serum neutrophil chemotactic activity (NCA) during bronchial challenge with {"}fog{"} with and without premedication with placebo, salbutamol, or SCG in 10 subjects with asthma, in four sets of studies. To assess changes in airway caliber, we measured FEV1. To assess changes in NCA, we measured the maximal distance reached by neutrophils in a filter when neutrophils were challenged with the subject's serum in a Boyden chamber. Treatment with placebo did not change baseline FEV1 or serum NCA; however, FEV1 decreased and serum NCA increased (p <0.05) after inhalation of {"}fog.{"} Treatment with SCG did not affect either FEV1 and baseline serum NCA. After inhalation of {"}fog,{"} no significant bronchoconstriction nor NCA increase was observed in eight of 10 patients with maximal mean percent decrease in FEV1 of -4.26, SEM 0.99, and maximal mean percent increase in NCA of +8.6, SEM 5.28. In the two patients who developed a bronchoconstriction after challenge with SCG pretreatment, an associated significant increase in NCA was observed but did not affect baseline NCA. After inhalation of {"}fog,{"} no significant decrease in FEV1 (maximal mean percent decrease FEV1, -6.71, SEM 0.17) nor significant increase in serum NCA (maximal mean percent increase NCA, +3.6, SEM 7.1) was observed in nine of 10 patients. After salbutamol, only one patient developed a bronchoconstrictive response to {"}fog{"} associated with a significant increase in serum NCA. These results suggest that both SCG and salbutamol may prevent the bronchoconstriction induced by {"}fog{"} by inhibiting mediator release.",
author = "Gianna Moscato and Ciro Rampulla and Antonio Dellabianca and Ercole Zanotti and Stefano Candura",
year = "1988",
doi = "10.1016/0091-6749(88)90009-7",
language = "English",
volume = "82",
pages = "382--388",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3 PART 1",

}

TY - JOUR

T1 - Effect of salbutamol and inhaled sodium cromoglycate on the airway and neutrophil chemotactic activity in "fog"-induced bronchospasm

AU - Moscato, Gianna

AU - Rampulla, Ciro

AU - Dellabianca, Antonio

AU - Zanotti, Ercole

AU - Candura, Stefano

PY - 1988

Y1 - 1988

N2 - To investigate whether salbutamol and sodium cromoglycate (SCG) inhibit airway response and the associated mediator release induced by ultrasonic nebulation of distilled water (UNDW, "fog"), we measured the serum neutrophil chemotactic activity (NCA) during bronchial challenge with "fog" with and without premedication with placebo, salbutamol, or SCG in 10 subjects with asthma, in four sets of studies. To assess changes in airway caliber, we measured FEV1. To assess changes in NCA, we measured the maximal distance reached by neutrophils in a filter when neutrophils were challenged with the subject's serum in a Boyden chamber. Treatment with placebo did not change baseline FEV1 or serum NCA; however, FEV1 decreased and serum NCA increased (p <0.05) after inhalation of "fog." Treatment with SCG did not affect either FEV1 and baseline serum NCA. After inhalation of "fog," no significant bronchoconstriction nor NCA increase was observed in eight of 10 patients with maximal mean percent decrease in FEV1 of -4.26, SEM 0.99, and maximal mean percent increase in NCA of +8.6, SEM 5.28. In the two patients who developed a bronchoconstriction after challenge with SCG pretreatment, an associated significant increase in NCA was observed but did not affect baseline NCA. After inhalation of "fog," no significant decrease in FEV1 (maximal mean percent decrease FEV1, -6.71, SEM 0.17) nor significant increase in serum NCA (maximal mean percent increase NCA, +3.6, SEM 7.1) was observed in nine of 10 patients. After salbutamol, only one patient developed a bronchoconstrictive response to "fog" associated with a significant increase in serum NCA. These results suggest that both SCG and salbutamol may prevent the bronchoconstriction induced by "fog" by inhibiting mediator release.

AB - To investigate whether salbutamol and sodium cromoglycate (SCG) inhibit airway response and the associated mediator release induced by ultrasonic nebulation of distilled water (UNDW, "fog"), we measured the serum neutrophil chemotactic activity (NCA) during bronchial challenge with "fog" with and without premedication with placebo, salbutamol, or SCG in 10 subjects with asthma, in four sets of studies. To assess changes in airway caliber, we measured FEV1. To assess changes in NCA, we measured the maximal distance reached by neutrophils in a filter when neutrophils were challenged with the subject's serum in a Boyden chamber. Treatment with placebo did not change baseline FEV1 or serum NCA; however, FEV1 decreased and serum NCA increased (p <0.05) after inhalation of "fog." Treatment with SCG did not affect either FEV1 and baseline serum NCA. After inhalation of "fog," no significant bronchoconstriction nor NCA increase was observed in eight of 10 patients with maximal mean percent decrease in FEV1 of -4.26, SEM 0.99, and maximal mean percent increase in NCA of +8.6, SEM 5.28. In the two patients who developed a bronchoconstriction after challenge with SCG pretreatment, an associated significant increase in NCA was observed but did not affect baseline NCA. After inhalation of "fog," no significant decrease in FEV1 (maximal mean percent decrease FEV1, -6.71, SEM 0.17) nor significant increase in serum NCA (maximal mean percent increase NCA, +3.6, SEM 7.1) was observed in nine of 10 patients. After salbutamol, only one patient developed a bronchoconstrictive response to "fog" associated with a significant increase in serum NCA. These results suggest that both SCG and salbutamol may prevent the bronchoconstriction induced by "fog" by inhibiting mediator release.

UR - http://www.scopus.com/inward/record.url?scp=0023773169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023773169&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(88)90009-7

DO - 10.1016/0091-6749(88)90009-7

M3 - Article

C2 - 3139728

AN - SCOPUS:0023773169

VL - 82

SP - 382

EP - 388

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3 PART 1

ER -